Results 31 to 40 of about 1,123 (151)

Diagnostic and disease severity determination criteria for hydroa vacciniforme lymphoproliferative disorders and severe mosquito bite allergy

The Journal of Dermatology, Volume 50, Issue 7, Page e198-e205, July 2023., 2023
Abstract Hydroa vacciniforme lymphoproliferative disorder (HV‐LPD) and severe mosquito bite allergy (SMBA) are both cutaneous forms of Epstein–Barr virus (EBV)‐associated T/natural killer (NK) cell LPDs and are closely related to chronic active EBV disease (CAEBV) and EBV‐associated hemophagocytic lymphohistiocytosis (EBV‐HLH).
Yoji Hirai, Hideo Asada, Toshihisa Hamada, Jun‐ichi Kawada, Hiroshi Kimura, Ayako Arai, Koichi Ohshima, Shouichi Ohga, Keiji Iwatsuki, Committee for Guidelines for the Management of Chronic Active EBV Disease and Related Disorders (the MHLW Research Team in Japan)   +9 more
wiley   +1 more source

Safety and effectiveness of dupilumab in the real‐world treatment of atopic dermatitis in Japan: 1‐year interim analysis from a post‐marketing surveillance

Journal of Cutaneous Immunology and Allergy, Volume 6, Issue 3, Page 78-87, June 2023., 2023
Patients with moderate‐to‐severe atopic dermatitis (AD) who initiated treatment with dupilumab between July 2019 and June 2020 in Japan were enrolled in this post‐marketing surveillance. At the interim data cut‐off, dupilumab appeared to be a safe and effective treatment option for patients aged ≥ 15 years with moderate‐to‐severe AD in routine clinical
Hidehisa Saeki, Hiroyuki Fujita, Katsuhisa Suzuki, Kazuhiko Arima   +3 more
wiley   +1 more source

Eczema herpeticum and impetigo herpetiformis, is there a link?

JEADV Clinical Practice, Volume 2, Issue 1, Page 140-143, March 2023., 2023
Abstract Impetigo herpetiformis (IH) is a rare variant of pustular psoriasis with typical onset during the third trimester of pregnancy; it is characterized by erythematous plaques lined with sterile pustules and sometimes there may be systemic involvement.
Fortunato Cassalia, Jacopo Tartaglia, Davide Zardo, Francesca Caroppo, Anna Belloni Fortina   +4 more
wiley   +1 more source

Recent advance in management of herpes simplex in Japan

The Journal of Dermatology, Volume 50, Issue 3, Page 299-304, March 2023., 2023
Abstract Herpes simplex, a common infection caused by the herpes simplex virus (HSV), is transmitted through contact of the skin/mucous membrane and establishes latency in the sensory ganglia for the rest of the life of the host. HSV occasionally reactivates and forms blisters around the lips or genitalia in some patients. Repeated overt symptoms, and,
Shinichi Imafuku
wiley   +1 more source

Kaposi Varicelliform Eruption: A Dermatologic Complication

Actas Dermo-Sifiliográficas (English Edition), 2017
I, Pérez-López, G, Blasco-Morente, A, Martínez-López, J, Tercedor-Sánchez   +3 more
semanticscholar   +4 more sources

Evaluation of standard treatments for managing adult Japanese patients with inadequately controlled moderate‐to‐severe atopic dermatitis: Two‐year data from the ADDRESS‐J disease registry

The Journal of Dermatology, Volume 49, Issue 9, Page 903-911, September 2022., 2022
Abstract Atopic dermatitis (AD), a chronic relapsing inflammatory skin disease with a high disease burden, is one of the most common dermatological conditions in Japan. Herein, we report the disease profiles and current AD treatment during 2‐year management of Japanese adults with moderate‐to‐severe AD.
Norito Katoh, Hidehisa Saeki, Yoko Kataoka, Takafumi Etoh, Satoshi Teramukai, Hiroki Takagi, Hiroyuki Fujita, Marius Ardeleanu, Elena Rizova, Kazuhiko Arima, the ADDRESS‐J Investigators   +10 more
wiley   +1 more source

Efficacy and safety of baricitinib in combination with topical corticosteroids in patients with moderate‐to‐severe atopic dermatitis with inadequate response, intolerance or contraindication to ciclosporin: results from a randomized, placebo‐controlled, phase III clinical trial (BREEZE‐AD4)*

British Journal of Dermatology, Volume 187, Issue 3, Page 338-352, September 2022., 2022
Baricitinib 4 mg + TCS improved the signs and symptoms of moderate‐to‐severe AD through 52 weeks of treatment in patients with inadequate response, intolerance or contraindication to CA. The safety profile was consistent with previous studies of baricitinib in moderate‐to‐severe AD.
Thomas Bieber, Kristian Reich, Carle Paul, Yuichiro Tsunemi, Matthias Augustin, Jean‐Philippe Lacour, Pierre‐Dominique Ghislain, Yves Dutronc, Ran Liao, Fan E. Yang, Dennis Brinker, Amy M. DeLozier, Eric Meskimen, Jonathan M. Janes, Kilian Eyerich, on behalf of theBREEZE‐AD4 study group   +15 more
wiley   +1 more source

An integrated analysis of herpes virus infections from eight randomized clinical studies of baricitinib in adults with moderate‐to‐severe atopic dermatitis

Journal of the European Academy of Dermatology and Venereology, Volume 36, Issue 9, Page 1486-1496, September 2022., 2022
Abstract Background Atopic dermatitis (AD) is associated with an increased risk for viral infections including those caused by herpes simplex virus and varicella zoster virus. Objectives This study examined treatment‐emergent (TE) herpes simplex infection including eczema herpeticum (EH), and herpes zoster (HZ), in adult patients with AD receiving ≥1 ...
T. Werfel, A.D. Irvine, C. Bangert, J. Seneschal, S. Grond, T. Cardillo, D. Brinker, J. Zhong, E. Riedl, A. Wollenberg   +9 more
wiley   +1 more source

Kaposi's Varicelliform-Like Eruption in a Patient Treated with Everolimus for Metastatic Renal Cell Carcinoma: Report of a Rare Case

Case Reports in Oncology, 2014
Kaposi's varicelliform eruption is a cutaneous eruption caused by the herpes simplex virus and a few other viruses that infect persons with pre-existing dermatosis such as atopic dermatitis.
Soojung Hong, Eun Hye Kim, Sung Bin Cho, Sun Young Rha   +3 more
doaj   +1 more source

Clinical effect of delgocitinib 0.5% ointment on atopic dermatitis eczema intensity and skin barrier function

Journal of Cutaneous Immunology and Allergy, Volume 5, Issue 2, Page 38-46, April 2022., 2022
The study by Abe et al examines the effects of delgocitinib 0.5% ointment treatment on skin rash severity and skin‐barrier function in adult patients with mild‐moderate AD. Partial eczema area and severity index (pEASI) score, stratum corneum hydration (SCH) and trans‐epidermal water‐loss (TEWL) were examined.
Masatoshi Abe, Hajime Iizuka, Ikue Nemoto‐Hasebe, Osamu Nemoto, Hiroyuki Toyama, Katsuyo Ohashi‐Doi, Kenji Kabashima   +6 more
wiley   +1 more source